Comparison of olanzapine versus fosaprepitant when given in combination with palonosetron and dexamethasone in preventing nausea and vomiting in highly emetogenic chemotherapy (HEC) and radiation therapy receiving patients

Trial Profile

Comparison of olanzapine versus fosaprepitant when given in combination with palonosetron and dexamethasone in preventing nausea and vomiting in highly emetogenic chemotherapy (HEC) and radiation therapy receiving patients

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Fosaprepitant (Primary) ; Cisplatin; Dexamethasone; Olanzapine; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2015 New trial record
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top